S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Evacuations urged in Ohio town as train wreck smolders
Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
NASDAQ:AFMD

Affimed - AFMD Stock Forecast, Price & News

$1.20
-0.08 (-6.25%)
(As of 02/3/2023 09:03 PM ET)
Add
Compare
Today's Range
$1.19
$1.28
50-Day Range
$1.06
$2.14
52-Week Range
$1.03
$5.10
Volume
1.31 million shs
Average Volume
1.70 million shs
Market Capitalization
$148.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.71

Affimed MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
459.5% Upside
$6.71 Price Target
Short Interest
Healthy
2.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.61) to ($0.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

162nd out of 1,025 stocks

Pharmaceutical Preparations Industry

72nd out of 498 stocks

AFMD stock logo

About Affimed (NASDAQ:AFMD) Stock

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Stock News Headlines

Short Interest in Affimed (NASDAQ:AFMD) Drops By 15.0%
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Why Shares of Affimed Fell Thursday
Affimed Third Quarter 2022 Earnings: Beats Expectations
Why Affimed Stock Plummeted by Over 16% Today
Affimed N.V. (AFMD)
See More Headlines
Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

AFMD Company Calendar

Last Earnings
11/15/2022
Today
2/06/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
197
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.71
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+459.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-68,060,000.00
Net Margins
-189.04%
Pretax Margin
-190.34%

Debt

Sales & Book Value

Annual Sales
$47.76 million
Book Value
$1.30 per share

Miscellaneous

Free Float
118,730,000
Market Cap
$148.10 million
Optionable
Optionable
Beta
2.35

Key Executives

  • Adolf Hoess
    Chief Executive Officer
  • Wolfgang Fischer
    Chief Operating Officer
  • Angus W. Smith
    Chief Financial Officer
  • Andreas Harstrick
    Chief Medical Officer
  • Arndt Schottelius
    Chief Scientific Officer













AFMD Stock - Frequently Asked Questions

Should I buy or sell Affimed stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings
or view top-rated stocks.

What is Affimed's stock price forecast for 2023?

6 brokers have issued 12-month target prices for Affimed's shares. Their AFMD share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $6.71 in the next twelve months. This suggests a possible upside of 459.5% from the stock's current price.
View analysts price targets for AFMD
or view top-rated stocks among Wall Street analysts.

How have AFMD shares performed in 2023?

Affimed's stock was trading at $1.24 on January 1st, 2023. Since then, AFMD stock has decreased by 3.2% and is now trading at $1.20.
View the best growth stocks for 2023 here
.

Are investors shorting Affimed?

Affimed saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 3,410,000 shares, a decline of 15.0% from the December 31st total of 4,010,000 shares. Based on an average trading volume of 2,130,000 shares, the short-interest ratio is presently 1.6 days.
View Affimed's Short Interest
.

When is Affimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our AFMD earnings forecast
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) issued its quarterly earnings results on Tuesday, November, 15th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.08. The biopharmaceutical company had revenue of $15.01 million for the quarter, compared to analysts' expectations of $7.66 million. Affimed had a negative trailing twelve-month return on equity of 48.46% and a negative net margin of 189.04%.

What other stocks do shareholders of Affimed own?
What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.73%), Intellectus Partners LLC (0.30%), Knights of Columbus Asset Advisors LLC (0.19%), Harbor Investment Advisory LLC (0.06%), Diversified Trust Co (0.04%) and SG Americas Securities LLC (0.02%).

How do I buy shares of Affimed?

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $1.20.

How much money does Affimed make?

Affimed (NASDAQ:AFMD) has a market capitalization of $148.10 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

How many employees does Affimed have?

The company employs 197 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 2/6/2023 by MarketBeat.com Staff